Navigation Links
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
Date:5/14/2013

FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering – vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise – as well as his leadership experience – will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Prior to joining Zosano Pharma, Mr. Oza served as Vice President, Chemistry, Manufacturing and Controls at Talon Therapeutics. He previously held the position of Vice President, Manufacturing and Supply Chain Operations at Jazz Pharmaceuticals and at Connetics Corporation (now a part of GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now part of Johnson and Johnson) in Product Development, Quality and Technical and Manufacturing Operations, progressing to his role as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, pursued graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

"This is an exciting
'/>"/>

SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
2. Zosano Pharma, Inc. Announces Key Strategic Hire
3. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... March 8, 2012 , Quality of Life ... available treatment fails in two thirds of patients ... Pevion Biotech AG today announced results from a large, ... vulvovaginal candidiasis (RVVC) patients. It is the first time that ...
... Inc. (Nasdaq: BIOD ) today announced that ... will present a corporate update at the ROTH 24th Annual ... 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ... Conference will be held March 11-14, 2012, at the ...
Cached Medicine Technology:Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 2Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 3Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 4
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... show signs of chronic inflammation in non-cancerous prostate tissue ... prostate cancer than those with no inflammation, according to ... the Johns Hopkins Kimmel Cancer Center. , The link ... men with so-called high-grade prostate cancer those with ... the presence of the most aggressive and rapidly growing ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... of DNA testing and genetic profiling is proving many skeptics wrong. ... tests outweigh consumers, privacy concerns. From dating, through genealogy, to ... health and lifestyle decisions is gaining acceptance. , ... ...
... OBESE MAY CARRY ASTHMA TRAIT , A new study ... carry a specific trait or phenotype that causes them ... not obese with asthma. Researchers from Quebec, Canada compared ... counts, symptom perceptions, BMI/waist circumference, and waist-to-hip ratio of ...
... Aug. 4 The Kansas Health Policy,Authority (KHPA) has ... enable the agency to analyze the cost and effectiveness ... of a data repository and a data analytic,interface (DAI) ... several,state programs. Andy Allison, KHPA,s deputy director and Medicaid ...
... HILL In the budding field of nanotechnology, scientists already ... the University of North Carolina at Chapel Hill have shown ... lead to new and more effective methods for treating cancer ... and obesity. , A team of researchers led by Joseph ...
... to start or continue smoking, researchers say , , MONDAY, Aug. ... appears to have a stronger effect in people who smoke, ... heart attack patients after the attack. It inhibits formation of ... 259 people given Plavix because of coronary conditions found that ...
... 2008 Revenue Increases 36% to $16.9 Million ... Sets Quarterly Record ... MINNEAPOLIS, Aug. 4 ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... results for the,second quarter ended June 28, 2008. Revenue for the ...
Cached Medicine News:Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 2Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 3Health News:Chest Journal: August news briefs 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 3Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 2Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 3Health News:Blood-Thinner Plavix Works Harder in Smokers 2Health News:ATS Medical Announces Second Quarter Results 2Health News:ATS Medical Announces Second Quarter Results 3Health News:ATS Medical Announces Second Quarter Results 4Health News:ATS Medical Announces Second Quarter Results 5Health News:ATS Medical Announces Second Quarter Results 6Health News:ATS Medical Announces Second Quarter Results 7Health News:ATS Medical Announces Second Quarter Results 8Health News:ATS Medical Announces Second Quarter Results 9Health News:ATS Medical Announces Second Quarter Results 10
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: